Included in the formulation
Eliso
lyophilizate
d / infusion
АТХ:A.16.A.B.11 Taliglucerase alpha
Pharmacodynamics:Analog glucocerebrosidase - a deficient enzyme in Gaucher's disease of type 1. Catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, preventing the accumulation of glucocerebroside in lysosomes, which leads to an increase in the liver and spleen, the development of anemia and thrombocytopenia.
Pharmacokinetics:After intravenous administration, the elimination half-life is 18-29 minutes. Elimination by the kidneys.
Indications:It is used to treat Gaucher's disease type 1 as a remedy for enzyme replacement therapy.
IV.E70-E90.E75.2 Other sphingolypidosis
Contraindications:Age before 2 years, severe renal and hepatic insufficiency, individual intolerance.
Carefully:Pregnancy and lactation, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - category is not defined. It is used with caution, in cases where the expected effect exceeds the risk to the fetus and newborn.
Dosing and Administration:Intravenously drip slowly for 60-120 minutes at a rate of no more than 2.2 ml / min, 60 U / kg body weight every 2 weeks.
The highest daily dose: 60 U / kg.
The highest single dose: 60 U / kg.
Side effects:Central and peripheral nervous system: headache, dizziness.
Respiratory system: pharyngitis, rhinorrhea.
The cardiovascular system: arterial hypertension, hot flashes.
Digestive system: nausea, vomiting.
Musculoskeletal system: arthralgia, low back pain.
Sense organs: blurred vision, lacrimation.
Dermatological reactions: a rash, itching.
Reproductive system: decreased libido.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:When taking the drug is not recommended driving and working with moving machinery.